Application of IL-27 receptor activator to preparation of products for treating obesity and complications thereof
A receptor activator, IL-27 technology, applied in medical preparations containing active ingredients, metabolic diseases, peptide/protein components, etc., to inhibit weight growth rate, alleviate macrophage infiltration, and improve insulin resistance Effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 2
[0029] Example 2: IL-27 can effectively inhibit the obesity process
[0030] After WT mice were fed with HFD for 4 weeks, some WT mice were intraperitoneally injected with recombinant IL-27 (100μg / mouse) (hereinafter referred to as rmIL-27) every other day, and another part of WT mice were injected intraperitoneally with the same amount of PBS every other day (Phosphate Buffered Saline, PH=7.4, standard biological buffer, as a control group). The body weight of the mice was monitored every 4 days and the mouse body weight growth rate was counted. The result is figure 2 As shown, compared with the mice injected with PBS solution, the weight gain trend of mice injected with rmIL-27 was significantly suppressed for 32 days. This example proves that recombinant IL-27 can effectively inhibit the obesity process.
Embodiment 3
[0031] Example 3: IL-27 can effectively reduce macrophage infiltration in adipose tissue
[0032] Studies have shown that obesity is a chronic low-grade inflammatory response, and the inflammatory factors in adipose tissue are mainly derived from macrophages. Macrophages can inhibit the differentiation of adipocytes and increase the expression of inflammatory response factors to cause insulin resistance. development of. In this example, adipose-infiltrated lymphocytes in the epididymis of WT mice that had been injected with rmIL-27 for 1 month were extracted, and the macrophages were labeled with F4 / 80 and CD11b fluorescent antibodies, and the macrophages were detected and counted by flow cytometry. Percentage of phages. The result is image 3 It is shown that IL-27 can effectively reduce macrophage infiltration in adipose tissue, showing that IL-27 has the potential to reduce obesity-related chronic inflammatory diseases such as diabetes caused by insulin resistance.
Embodiment 4
[0033] Example 4: rmIL-27 can improve insulin sensitivity in mice
[0034] In this implementation, through the insulin clamp experiment (ITT), WT mice that had been continuously injected with rmIL-27 for 1 month were fasted for 2 to 3 hours and then intraperitoneally injected with 0.5 U / Kg of insulin. The mice were tested with a blood glucose meter every 15 minutes. The blood glucose concentration was used to detect the insulin resistance of mice. The result is Figure 4 As shown, the sensitivity of WT mice injected with rmIL-27 to insulin in the insulin clamp test is better than that of control mice, which further proves that rmIL-27 can improve the insulin sensitivity of mice.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com